WO2003062234A1 - Composes de quinoxaline - Google Patents

Composes de quinoxaline Download PDF

Info

Publication number
WO2003062234A1
WO2003062234A1 PCT/JP2003/000545 JP0300545W WO03062234A1 WO 2003062234 A1 WO2003062234 A1 WO 2003062234A1 JP 0300545 W JP0300545 W JP 0300545W WO 03062234 A1 WO03062234 A1 WO 03062234A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
group
halogen
substituted
Prior art date
Application number
PCT/JP2003/000545
Other languages
English (en)
Japanese (ja)
Inventor
Kazuhisa Takayama
Naoyuki Masuda
Takeshi Hondo
Ryoji Hirabayashi
Norio Seki
Yuji Koga
Ryo Naito
Yoshinori Okamoto
Hiroyuki Kaizawa
Takao Okuda
Youhei Okada
Makoto Takeuchi
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to JP2003562112A priority Critical patent/JPWO2003062234A1/ja
Publication of WO2003062234A1 publication Critical patent/WO2003062234A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne des composés cliniquement efficaces qu'on peut utiliser comme remèdes contre diverses maladies dans lesquelles la poly(ADP-ribose) polymérase intervient (PARP), en particulier, des maladies inflammatoires telles que l'arthrite rhumatoïde. Cette invention concerne aussi des dérivés de quinoxaline possédant un groupe carbamoyle en position 5 et un ou des substituants en positions 2 et/ou 3, en particulier, des composés possédant un groupe hydrocarbure cyclique ou un groupe hétérocyclique substitué par Y1 Y2 R4 en position 3, ou des sels de ceux-ci répondant aux normes pharmaceutiques.
PCT/JP2003/000545 2002-01-23 2003-01-22 Composes de quinoxaline WO2003062234A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003562112A JPWO2003062234A1 (ja) 2002-01-23 2003-01-22 キノキサリン化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002014121 2002-01-23
JP2002-014121 2002-01-23

Publications (1)

Publication Number Publication Date
WO2003062234A1 true WO2003062234A1 (fr) 2003-07-31

Family

ID=27606086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/000545 WO2003062234A1 (fr) 2002-01-23 2003-01-22 Composes de quinoxaline

Country Status (2)

Country Link
JP (1) JPWO2003062234A1 (fr)
WO (1) WO2003062234A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014873A1 (fr) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. Derive de quinazoline-8-carboxyamide substitue en 4 et sel d'addition pharmaceutiquement acceptable de celui-ci
WO2006040192A1 (fr) * 2004-10-15 2006-04-20 Glaxo Group Limited Ligands de recepteurs histaminiques a base de derives pyrrolidiniques
EP1683523A1 (fr) * 2005-01-25 2006-07-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 2-phenylquinoxalines comme inhibiteurs de mpp1
JP2006519806A (ja) * 2003-03-07 2006-08-31 グラクソ　グループ　リミテッド 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
JPWO2005028438A1 (ja) * 2003-09-22 2007-11-15 萬有製薬株式会社 新規ピペリジン誘導体
WO2007078335A3 (fr) * 2005-12-21 2007-11-29 Decode Genetics Inc Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation
WO2008015429A2 (fr) * 2006-08-01 2008-02-07 Sentinel Oncology Limited Composés pharmaceutiques
JP2009530287A (ja) * 2006-03-13 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体
JP2009197010A (ja) * 2005-08-26 2009-09-03 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｐｐａｒアゴニスト活性を有する誘導体
KR100916716B1 (ko) * 2007-09-27 2009-09-10 한국화학연구원 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
US7592347B2 (en) 2003-04-23 2009-09-22 Glaxo Group Limited Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
JP2010537969A (ja) * 2007-08-31 2010-12-09 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプピペリジン化合物とその使用
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
WO2012085648A1 (fr) 2010-12-22 2012-06-28 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substitués par du phosphore et leurs utilisations
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
EP2537844A1 (fr) 2008-07-21 2012-12-26 Purdue Pharma L.P. Composés pipéridine à liaison et substitués par une quinoxaline, et leurs utilisations
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
WO2013080036A1 (fr) 2011-12-01 2013-06-06 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée par une azétidine et leurs utilisations
WO2014020405A1 (fr) 2012-07-30 2014-02-06 Purdue Pharma L.P. Composés de pipéridine cycliques de type quinoxaline substitués par un groupe dérivé d'urée ou un groupe dérivé de lactame et leurs utilisations
WO2014102589A1 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine du type quinazolin-4(3h)-one et utilisations de ceux-ci
WO2014102594A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations
WO2014102592A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée par oxime et leurs utilisations
WO2014102588A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type indole et indoline et leurs utilisations
WO2015163435A1 (fr) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
JP2016536302A (ja) * 2013-10-23 2016-11-24 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての置換されているキノキサリン誘導体
WO2017079641A1 (fr) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
WO2022194248A1 (fr) * 2021-03-18 2022-09-22 苏州国匡医药科技有限公司 Agent de dégradation à petites molécules ctla-4 et son utilisation
WO2023047107A1 (fr) * 2021-09-22 2023-03-30 The University Of Durham Composés dérivés aryles ou hétéroaryles pour traiter des infections microbiennes
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2024035627A1 (fr) * 2022-08-08 2024-02-15 Ajax Therapeutics, Inc. Composés d'urée et d'amide hétérocycliques en tant qu'inhibiteurs de jak2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
WO2001085687A1 (fr) * 2000-05-11 2001-11-15 Basf Ag Indoles substitues en tant qu'inhibiteurs de parp
WO2002068407A1 (fr) * 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
WO2001085687A1 (fr) * 2000-05-11 2001-11-15 Basf Ag Indoles substitues en tant qu'inhibiteurs de parp
WO2002068407A1 (fr) * 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014873A1 (fr) * 2002-08-09 2004-02-19 Kyorin Pharmaceutical Co., Ltd. Derive de quinazoline-8-carboxyamide substitue en 4 et sel d'addition pharmaceutiquement acceptable de celui-ci
JP2006519806A (ja) * 2003-03-07 2006-08-31 グラクソ　グループ　リミテッド 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
US7592347B2 (en) 2003-04-23 2009-09-22 Glaxo Group Limited Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
JPWO2005028438A1 (ja) * 2003-09-22 2007-11-15 萬有製薬株式会社 新規ピペリジン誘導体
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
WO2006040192A1 (fr) * 2004-10-15 2006-04-20 Glaxo Group Limited Ligands de recepteurs histaminiques a base de derives pyrrolidiniques
EP1683523A1 (fr) * 2005-01-25 2006-07-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 2-phenylquinoxalines comme inhibiteurs de mpp1
WO2006079478A1 (fr) * 2005-01-25 2006-08-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. 2-phenylquinoxalines comme inhibiteurs de mpp1
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
JP2009197010A (ja) * 2005-08-26 2009-09-03 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｐｐａｒアゴニスト活性を有する誘導体
US7750012B2 (en) 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
WO2007078335A3 (fr) * 2005-12-21 2007-11-29 Decode Genetics Inc Inhibiteurs de biaryl-azote-heterocycle de lta4h pour traiter l'inflammation
JP2009530287A (ja) * 2006-03-13 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高血圧、炎症および他の疾患の治療のための可溶性エポキシドヒドロラーゼの阻害剤としてのピペリジニル、インドリル、ピリニジル、モルホリニルおよびベンズイミダゾリル尿素誘導体
US8501783B2 (en) 2006-03-13 2013-08-06 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US9029550B2 (en) 2006-03-13 2015-05-12 The Regents Of The University Of California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
WO2008015429A3 (fr) * 2006-08-01 2008-10-02 Sentinel Oncology Ltd Composés pharmaceutiques
WO2008015429A2 (fr) * 2006-08-01 2008-02-07 Sentinel Oncology Limited Composés pharmaceutiques
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
US9527840B2 (en) 2007-08-31 2016-12-27 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
JP2010537969A (ja) * 2007-08-31 2010-12-09 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプピペリジン化合物とその使用
EP2433936A1 (fr) 2007-08-31 2012-03-28 Purdue Pharma LP Composés de pipéridine de type quinoxaline substituée et leurs utilisations
US9278967B2 (en) 2007-08-31 2016-03-08 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
EP3101018A1 (fr) 2007-08-31 2016-12-07 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée et leurs utilisations
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
EP3564240A1 (fr) 2007-08-31 2019-11-06 Purdue Pharma L.P. Derivés de pipéridine comme intermédiares
EP2433935A1 (fr) 2007-08-31 2012-03-28 Purdue Pharma LP Composés de pipéridine de type quinoxaline substituée et leurs utilisations
EP2433937A1 (fr) 2007-08-31 2012-03-28 Purdue Pharma LP Composés de pipéridine de type quinoxaline substituée et leurs utilisations
KR100916716B1 (ko) * 2007-09-27 2009-09-10 한국화학연구원 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
EP2537844A1 (fr) 2008-07-21 2012-12-26 Purdue Pharma L.P. Composés pipéridine à liaison et substitués par une quinoxaline, et leurs utilisations
US11111246B2 (en) 2008-07-21 2021-09-07 Purdue Pharma L.P. Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds
US10519156B2 (en) 2008-07-21 2019-12-31 Purdue Pharma L.P. 9′-Aza[3,9′-bi(bicyclo[3.3.1]nonan)]-3′-one and preparation thereof
US8476271B2 (en) 2008-07-21 2013-07-02 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US9890164B2 (en) 2008-07-21 2018-02-13 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US9145408B2 (en) 2008-07-21 2015-09-29 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
WO2012085648A1 (fr) 2010-12-22 2012-06-28 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substitués par du phosphore et leurs utilisations
WO2013080036A1 (fr) 2011-12-01 2013-06-06 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée par une azétidine et leurs utilisations
US9290488B2 (en) 2011-12-01 2016-03-22 Purdue Pharma L.P. Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014020405A1 (fr) 2012-07-30 2014-02-06 Purdue Pharma L.P. Composés de pipéridine cycliques de type quinoxaline substitués par un groupe dérivé d'urée ou un groupe dérivé de lactame et leurs utilisations
WO2014102589A1 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine du type quinazolin-4(3h)-one et utilisations de ceux-ci
WO2014102592A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée par oxime et leurs utilisations
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9598411B2 (en) 2012-12-27 2017-03-21 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102594A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations
WO2014102588A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type indole et indoline et leurs utilisations
JP2016536302A (ja) * 2013-10-23 2016-11-24 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての置換されているキノキサリン誘導体
WO2015163435A1 (fr) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
US9783522B2 (en) 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
WO2017079641A1 (fr) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. Dérivés de n-[2-(1-benzylpipéridin-4-yl)éthyl]-4-(pyrazin-2-yl)-pipérazine-1-carboxamide et composés apparentés en tant qu'antagonistes du récepteur muscarinique 4 (m4) pour le traitement de maladies neurologiques
US11033539B2 (en) 2015-11-06 2021-06-15 Neurocrine Biosciences, Inc. Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
EA039638B1 (ru) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Антагонисты мускаринового рецептора 4 и способы их применения
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2022194248A1 (fr) * 2021-03-18 2022-09-22 苏州国匡医药科技有限公司 Agent de dégradation à petites molécules ctla-4 et son utilisation
WO2023047107A1 (fr) * 2021-09-22 2023-03-30 The University Of Durham Composés dérivés aryles ou hétéroaryles pour traiter des infections microbiennes
WO2024035627A1 (fr) * 2022-08-08 2024-02-15 Ajax Therapeutics, Inc. Composés d'urée et d'amide hétérocycliques en tant qu'inhibiteurs de jak2

Also Published As

Publication number Publication date
JPWO2003062234A1 (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
WO2003062234A1 (fr) Composes de quinoxaline
WO2002068407A1 (fr) Compose benzimidazole
KR100979577B1 (ko) 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체
WO2001021615A1 (fr) Dérivés de benzimidazole
JP5798115B2 (ja) 置換ヒドロキサム酸およびその使用
US20040072867A1 (en) NK1 antagonists
SK18499A3 (en) Substituted pyrimidine derivatives and their pharmaceutical use
AU5793699A (en) Inhibitors of p38-alpha kinase
WO2006126676A1 (fr) Dérivé d'amine cyclique ayant un groupe alkyle substitué
WO1999055674A1 (fr) Derives de 1-[(1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes
WO1998039325A1 (fr) Derives 4,4-difluoro-2,3,4,5-tetrahydro-1h-1-benzazepines et compositions pharmaceutiques les contenant
JP2001512118A (ja) オキシドスクアレン−シクラーゼを阻害するピリジル−およびピリミジル複素環式化合物
TW200922588A (en) Pyrimidyl indoline compounds
WO2012041860A1 (fr) Utilisation de dérivés de benzazole en tant que ligands des récepteurs h4 de l'histamine
JP6585718B2 (ja) 抗ヒスタミン剤としての新規ベンゾイミダゾール誘導体
IL171332A (en) 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof and pharmaceutical compositions comprising them
EP1988075B1 (fr) Derive de pyrrole ou sel de celui-ci
WO2021060453A1 (fr) Dérivé d'amine secondaire optiquement actif réticulé
US5025033A (en) Alkylene diamines
US7176199B2 (en) Aryl-substituted alicyclic compound and medical composition comprising the same
JPH0832689B2 (ja) 新規ベンゾイソオキサゾールおよびベンゾイソチアゾール化合物、その製造法ならびに医薬品組成物
WO2001054726A1 (fr) REMEDES DESTINES A UNE LESION PAR REPERFUSION CONTENANT UN ANTAGONISTE D'INTEGRINE αvβ3
WO2005100341A1 (fr) Dérivé de 2-aminopyridine
WO2005073183A1 (fr) Derive de sulfure d’aryle
WO2001025199A1 (fr) Composes d'uree, procede de production et d'utilisation de ces derniers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003562112

Country of ref document: JP

122 Ep: pct application non-entry in european phase